# Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy

> **NCT02366871** · PHASE2 · COMPLETED · sponsor: **University of Colorado, Denver** · enrollment: 400 (actual)

## Conditions studied

- Gynecologic Cancer
- Venous Thromboembolism

## Interventions

- **DRUG:** Oral apixaban
- **DRUG:** Subcutaneous enoxaparin

## Key facts

- **NCT ID:** NCT02366871
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-28
- **Primary completion:** 2019-06
- **Final completion:** 2019-06
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2020-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02366871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02366871, "Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02366871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*